Cornerstone Therapeutics Inc.’s acquisition of privately held specialty pharma EKR Therapeutics Inc. adds momentum to its attempts at becoming a respiratory and acute care specialist. The transaction adds two commercial-stage hospital products to a portfolio already grown and pruned by a series of deals. Cornerstone will pay $125 million upfront for EKR and could owe potential milestone payments, the company announced May 14.
Cornerstone gains rights to Cardene IV (nicardipine), a drug used in hospitals for the short term treatment of hypertension when oral therapy is not feasible or desirable, and Retavase (reteplase), a biologic for the management of acute myocardial infarction, improvement of ventricular function following AMI and reduction of the incidence of congestive heart failure and mortality associated with AMI
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?